Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease

Theresa Louise Boye, Casper Steenholdt, Kim Bak Jensen, Ole Haagen Nielsen

7 Citationer (Scopus)

Abstract

The pathogenesis of inflammatory bowel diseases (IBD) involves genetic predisposition, environmental factors, and a broadly dysregulated intestinal immune response to the commensal intestinal microflora. The interface between genetic predisposition and environmental factors is reflected in the epigenetic regulation at the transcriptional level. Treatment targets now involve mucosal and histological healing, but the future might additionally include normalization of intestinal cellular functions also at the molecular level, for example comprising complete restoration of phenotypic, genotypic, and epigenetic states. Recent developments in patient-derived epithelial intestinal stem cell (ISC) organoid technologies have opened exciting new therapeutic opportunities to potentially attain molecular healing by combining stem cell therapy with molecular manipulations using (epi)drugs and/or CRISPR/Cas9 genome editing. Here, we are the first to discuss the possibility for phenotypic, genotypic, and epigenetic restoration via molecular manipulations and stem cell therapy in IBD from a clinical perspective.

OriginalsprogEngelsk
TidsskriftStem cells (Dayton, Ohio)
Vol/bind40
Udgave nummer5
Sider (fra-til)447-457
Antal sider11
ISSN1066-5099
DOI
StatusUdgivet - 27 maj 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater